Utama › Dermatitis Atopik (Eksim) › Texas
Kajian klinikal Dermatitis Atopik (Eksim) di Texas
18 kajian untuk Dermatitis Atopik (Eksim) sedang mencari peserta di lokasi di Texas.
Bandar di Texas
Teks kajian rasmi (Bahasa Inggeris)
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
- Clinical Site 102, College Station
- Clinical Site 104, San Antonio
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
Umur 18 hingga 65 · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07453602This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Reveal Research Institute - Dallas- Site Number : 8400012, Dallas
- Austin Institute for Clinical Research, Inc- Site Number : 8400030, Pflugerville
- Complete Dermatology - Sugar Land- Site Number : 8400001, Sugar Land
Mengambil pesertaKajian pemerhatian
Umur 12 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Arlington
- Novartis Investigative Site, Cypress
- Novartis Investigative Site, Dallas
- dan 2 lagi
Mengambil pesertaFasa 2
Umur 18 hingga 100 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Arlington
- Enveda Investigative Site, Houston
- Enveda Investigative Site, San Antonio
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07298395First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Texas Dermatology and Laser Specialists, San Antonio
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
Umur 18 hingga 65 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07527923A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Texas Dermatology and Laser Specialists, San Antonio
Mengambil pesertaFasa 3
Umur 2 hingga 11 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06807281A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Dallas
- Investigational Site, Frisco
- Investigational Site, San Antonio
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07003425Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
- Harrison Dermatology, Missouri City
Mengambil pesertaKajian pemerhatian
Umur 12 hingga 89 · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07645820A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
- ALS Global, Irving
Mengambil pesertaFasa 2/3
Umur 18 hingga 80 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07355075A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Progressive Clinical Research, PA, San Antonio
Mengambil pesertaFasa 2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT07599813A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 8, Southlake
Mengambil pesertaFasa 2
Umur 18 hingga 74 · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT07037901A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Dallas
- Enveda Investigative Site, San Antonio
- Enveda Investigative Site, Sugar Land
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT07643766A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Arlington Research Center, Inc /ID# 266330, Arlington
- 3A Research - East location /ID# 267622, El Paso
- Prime Clinical Research - Mansfield - East Broad Street /ID# 268042, Mansfield
- dan 2 lagi
Mengambil pesertaFasa 3
Umur 2 hingga 11 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06461897A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Arlington Research Center, Inc /ID# 263665, Arlington
- Studies in Dermatology LLC /ID# 263335, Cypress
- Dermatology Treatment and Research Center /ID# 265812, Dallas
- dan 6 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 63 · Semua jantina · Dikemas kini 6 Jul 2026 · NCT06389136Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
- UT Health Science Houston, Bellaire
- Center for Clinical Studies, Webster
Mengambil pesertaFasa 2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 15 Jun 2026 · NCT06397911A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Dermatology Treatment and Research Center, Dallas
- North Texas Center for Clinical Research, Frisco
- DCT-Stone Oak, LLC dba Discovery Clinical Trials, San Antonio
- dan 1 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Mei 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7082, Cedar Park
- Galderma Investigational Site 8238, Dallas
- Galderma Investigational Site 7062, Edinburg
- dan 3 lagi
Mengambil pesertaKajian pemerhatian
Umur 12 ke atas · Semua jantina · Dikemas kini 13 Mac 2026 · NCT06988605Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
- Clinical Investigations of Texas, Dallas
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Dis 2025 · NCT06982352Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.